Circulating von Willebrand factor antigen II in atherosclerosis: A comparison with von Willebrand factor and soluble thrombomodulin

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 3, 1998, Pages 261-266

  Blann, A D ^a   De Romeuf, C ^b   Mazurier, C ^c   McCollum, C N ^b  

^a CITY HOSPITAL   (United Kingdom)

^b Laboratoire de recherche   (France)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atherosclerosis; Von Willebrand factor; Von Willebrand factor antigen II

Indexed keywords

THROMBOMODULIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND PROPOLYPEPTIDE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTOPENIA;

EID: 0031859107     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199804000-00007     Document Type: Article

References (17)

1. Wagner DD. The cell biology of von Willebrand factor. Anna Rev Cell Biol 1990; 6: 217-246.
2. McCarroll DR, Ruggeri ZM, Montgomery RR. Correlation between levels of von Willebrand's antigen II and von Willebrand factor: discrimination between type I and type II .von Willebrand's disease. J Lab Clin Med 1984; 103: 704-711.
3. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand factor antigen II) after secretion from endothelial cells. Proc NatlAcadSd USA 1987; 84: 1955-1959.
4. Blann AD, Seigneur M. Soluble markers of endothelial cell function. Clin Hemorheol 1997; 17: 3-11.
5. Blann AD, Sheeran TP, Emery P. Von Willebrand factor: increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br ] Biomed Set 1997; 54: 5-9.
6. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
7. Wallberg-Jonsson S, Dahlen GH, Nilsson TK, Ranby M, Rantappa-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rhettmatol 1993; 12:318-324.
8. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 1993; 71: 423-431.
9. Boffa MC. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker. Haemostasis 1996; 26: 233-243.
10. Amiral J, Adam M, Mimilla F, Larrivaz I, Chambrette B, Boffa MC. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies on plasma. Hybridoma 1995; 13: 205-213.
11. Palomaki P, Miettinin H, Mustaniemi H. Diagnosis of acute myocardial infarction by MONICA and FINMONICA diagnostic criteria in corriparison with hospital discharge diagnosis. / Clin Epidemiol 1994; 47: 659-666.
12. Romeuf C, Mazurier C. Comparison between plasma von Willebrand factor (VWF) and VWF antigen II levels in normal individuals and patients with von Willebrand disease. Thromb Haemost 1998; in press.
13. Vischer UM, Ingerslev J, Wollheim CB, Mestries JC, Tsakiris DA, Haefeli W, et al. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWfAgll) levels. Thromb Haemost 1997; 77: 387-393.
14. Borchinellini A, Fijnvandrat K, ten Gate JW, Pajkrt D, van Deventer SJH, Pasterkamp G, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxaemia and administration of l-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-2958.
15. van Mourik JA, Fijnheer R, Voorberg J, Brinkman HJM. The molar ratio of von Willebrand factor to its propeptides is a marker of endothelial cell perturbation in vivo [abstract]. Thromb Haemost 1997; 73 (suppl): 701.
16. Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 1997; 58: 115-120.
17. De Jong SC, Stehouwer CD A, van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinaemia. Thromb Haemost 1997; 78: 1332-1337.